Sila-CBD Derivatives as Inhibitors of Heme-Induced NLRP3 Inflammasome: Application in Hemolytic Diseases
- 6 November 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (12) , 1716-1723
Abstract
Synthesis and biological evaluation of silicon-incorporated phytocannabinoids with improved pharmacological properties toward inflammatory diseases are described. The synthesized sila-analogues 15a, 15b, and 15c displayed potent inhibition of pro-inflammatory cytokines, including IL-1β, TNF-α, and IL-6 at 10 μM. Further, the release of heme during the lysis of red blood cells in hemolytic diseases is one of the major reasons for inflammation associated with the pathophysiology of these diseases. Due to scanty literature related to inhibitors of heme-mediated induction of the NLRP3 inflammasome, we decided to test these compounds against it. Compounds 15a and 15c significantly inhibited the heme-mediated induction of the NLRP3 inflammasome at a concentration of 0.1 μM. Interestingly, the sila-CBD derivatives also showed higher metabolic stability in contrast to their carbon analogues. Anti-NLRP3 inflammasome activity of compounds 15a and 15c were further validated in vivo against heme-mediated peritoneal inflammation. The anti-inflammatory activity of these compounds could be useful in treating diseases such as sickle cell anemia and thalassemia involving the hemolysis-mediated activation of the NLRP3 inflammasome.Keywords
Funding Information
- Council of Scientific and Industrial Research, India (HCP 0023)
- Anusandhan National Research Foundation (JCB/2021/000022/SSC)
This publication has 44 references indexed in Scilit:
- Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer’s DiseaseMolecular Pharmacology, 2011
- Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymesBritish Journal of Pharmacology, 2010
- Evidence that the plant cannabinoid cannabigerol is a highly potent α2‐adrenoceptor agonist and moderately potent 5HT1Areceptor antagonistBritish Journal of Pharmacology, 2010
- Cannabidiol for the treatment of psychosis in Parkinson’s diseaseJournal of Psychopharmacology, 2008
- Nonpsychoactive Cannabidiol Prevents Prion Accumulation and Protects Neurons against Prion ToxicityJournal of Neuroscience, 2007
- Synthesis and Antitumor Activity of Quinonoid Derivatives of CannabinoidsJournal of Medicinal Chemistry, 2004
- Neuroprotective effect of cannabidiol, a non‐psychoactive component fromCannabis sativa, on β‐amyloid‐induced toxicity in PC12 cellsJournal of Neurochemistry, 2004
- Clinical applications of quinone-containing alkylating agentsFrontiers in Bioscience-Landmark, 2000
- Sila-substitution — a useful strategy for drug design?Endeavour, 1986
- Hashish—XIIITetrahedron, 1968